Seroatlas · Human Serome Atlas

SPTLC2

Serine palmitoyltransferase 2

Also known as: hLCB2a, KIAA0526, LCB2, LCB2A, SPTC2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O15270
Gene
SPTLC2
Ensembl
ENSG00000100596
Chromosome
14
Canonical length
562 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted membrane proteins
Subcellular location
Plasma membrane,Cell Junctions

OverviewNCBI Gene

This gene encodes a long chain base subunit of serine palmitoyltransferase. Serine palmitoyltransferase, which consists of two different subunits, is the key enzyme in sphingolipid biosynthesis. It catalyzes the pyridoxal-5-prime-phosphate-dependent condensation of L-serine and palmitoyl-CoA to 3-oxosphinganine. Mutations in this gene were identified in patients with hereditary sensory neuropathy type I. [provided by RefSeq, Mar 2011]

Canonical amino-acid sequenceUniProt

562 residues, UniProt reviewed canonical sequence.

>O15270|SPTLC2
     1  MRPEPGGCCC RRTVRANGCV ANGEVRNGYV RSSAAAAAAA AAGQIHHVTQ NGGLYKRPFN
    61  EAFEETPMLV AVLTYVGYGV LTLFGYLRDF LRYWRIEKCH HATEREEQKD FVSLYQDFEN
   121  FYTRNLYMRI RDNWNRPICS VPGARVDIME RQSHDYNWSF KYTGNIIKGV INMGSYNYLG
   181  FARNTGSCQE AAAKVLEEYG AGVCSTRQEI GNLDKHEELE ELVARFLGVE AAMAYGMGFA
   241  TNSMNIPALV GKGCLILSDE LNHASLVLGA RLSGATIRIF KHNNMQSLEK LLKDAIVYGQ
   301  PRTRRPWKKI LILVEGIYSM EGSIVRLPEV IALKKKYKAY LYLDEAHSIG ALGPTGRGVV
   361  EYFGLDPEDV DVMMGTFTKS FGASGGYIGG KKELIDYLRT HSHSAVYATS LSPPVVEQII
   421  TSMKCIMGQD GTSLGKECVQ QLAENTRYFR RRLKEMGFII YGNEDSPVVP LMLYMPAKIG
   481  AFGREMLKRN IGVVVVGFPA TPIIESRARF CLSAAHTKEI LDTALKEIDE VGDLLQLKYS
   541  RHRLVPLLDR PFDETTYEET ED

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SPTLC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
30 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 30 nTPM
  • esophagus: 20 nTPM
  • stomach: 17 nTPM
  • placenta: 17 nTPM
  • adipose tissue: 16 nTPM
  • colon: 15 nTPM

Single-cell type

  • neutrophils: 1,179 nCPM
  • tuft cells: 830 nCPM
  • neutrophil progenitors: 656 nCPM
  • monocyte progenitors: 566 nCPM
  • esophageal apical cells: 494 nCPM
  • monocytes: 380 nCPM

Immune cell

  • non-classical monocyte: 32 nTPM
  • classical monocyte: 31 nTPM
  • myeloid DC: 31 nTPM
  • eosinophil: 27 nTPM
  • intermediate monocyte: 24 nTPM
  • neutrophil: 19 nTPM

Brain region

  • white matter: 98 nTPM
  • medulla oblongata: 62 nTPM
  • spinal cord: 50 nTPM
  • basal ganglia: 50 nTPM
  • pons: 50 nTPM
  • cerebellum: 49 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SPTLC2.

Disease | AllUniProt

Conditions SPTLC2 is implicated in, by any mechanism.

Disease | GeneticClinVar

10 pathogenic / likely-pathogenic of 700 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on SPTLC2 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.39
gnomAD pLI
0.78
gnomAD missense Z
2.04
DepMap mean gene effect
-0.28
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SPTLC2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SPTLC2 as an antibody target. Whether an autoantibody or antibody against SPTLC2 could matter depends on whether native SPTLC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SPTLC2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SPTLC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SPTLC2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...